Understanding how antibodies protect against Clostridium difficile infection
Characterization of neutralizing antitoxins and epitopes in Clostridium difficile patients
['FUNDING_R01'] · UNIVERSITY OF MARYLAND BALTIMORE · NIH-10748404
This study is looking at how your immune system fights off Clostridium difficile infection (CDI) by focusing on the antibodies that help protect you from the harmful toxins made by the bacteria, and if you join, you can help researchers learn more about these protective responses by providing samples.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MARYLAND BALTIMORE (nih funded) |
| Locations | 1 site (BALTIMORE, UNITED STATES) |
| Trial ID | NIH-10748404 on ClinicalTrials.gov |
What this research studies
This research investigates the immune response in patients with Clostridium difficile infection (CDI), focusing on the antibodies that protect against the harmful toxins produced by the bacteria. The researchers aim to identify specific types of antibodies and their binding sites, known as epitopes, that are crucial for effective immunity. By analyzing B cell responses and cloning neutralizing antibodies, the study seeks to develop a better understanding of how these immune components can prevent severe CDI and its recurrence. Patients may contribute to this research by providing samples that help characterize these protective responses.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who have been diagnosed with Clostridium difficile infection and are experiencing symptoms.
Not a fit: Patients who do not have Clostridium difficile infection or those who have already recovered from it may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments and preventive strategies for patients suffering from Clostridium difficile infections.
How similar studies have performed: Previous research has shown that understanding antibody responses can lead to significant advancements in treating infectious diseases, suggesting that this approach has potential for success.
Where this research is happening
BALTIMORE, UNITED STATES
- UNIVERSITY OF MARYLAND BALTIMORE — BALTIMORE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: FENG, HANPING — UNIVERSITY OF MARYLAND BALTIMORE
- Study coordinator: FENG, HANPING
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.